<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of apnea of prematurity
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of apnea of prematurity
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of apnea of prematurity
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard Martin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph A Garcia-Prats, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George B Mallory, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 30, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Apnea of prematurity is a developmental disorder in preterm infants, which occurs as a direct consequence of immature respiratory control. Apneic spells are considered clinically significant if the episodes last &gt;20 seconds or are accompanied by hypoxemia and/or bradycardia. The frequency and severity of symptoms is inversely proportional to gestational age (GA); almost all extremely preterm (EPT; GA &lt;28 weeks) and extremely low birth weight (ELBW; BW &lt;1000 g) infants are affected.
        </p>
        <p>
         The management of apnea of prematurity will be reviewed here. The pathogenesis, clinical features, and diagnosis of apnea of prematurity are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5052.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H778059835">
         <span class="h1">
          MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preterm infants &lt;35 weeks gestational age (GA) should be monitored for apnea because of the high prevalence of apnea in this group of patients [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5052.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity", section on 'Incidence'
         </a>
         .)
        </p>
        <p>
         Monitoring for apnea of prematurity and associated bradycardia and hypoxemia generally includes
         <strong>
          all
         </strong>
         of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continuous cardiac monitoring
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continuous pulse oximetry (see
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'Pulse oximetry'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Impedance pneumography – The accuracy of pneumography is limited by movement artifacts and the inability to detect obstructive apnea episodes. For this reason, it is generally
         <strong>
          not
         </strong>
         used alone to detect apnea.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1130910519">
         <span class="h1">
          CLINICALLY SIGNIFICANT APNEA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optimal thresholds to determine clinically significant apnea events have not been established. In our practice, we use the following threshold settings to detect clinically significant episodes of apnea (see
         <a class="medical medical_review" href="/z/d/html/5052.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity", section on 'Diagnosis'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Apnea ≥15 or 20 seconds – The lower threshold may be used prior to discharge (see
         <a class="local">
          'Discharge planning'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heart rate ≤70 or 80 beats per minute
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) &lt;80 or 85 percent
        </p>
        <p>
        </p>
        <p>
         Other centers may use different parameters.
        </p>
        <p class="headingAnchor" id="H17699592">
         <span class="h1">
          MANAGEMENT OVERVIEW
         </span>
        </p>
        <p class="headingAnchor" id="H3387901292">
         <span class="h2">
          Prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prophylactic
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         therapy is suggested for extremely preterm (EPT; gestational age &lt;28 weeks) since apnea occurs in nearly all of these infants and treatment may reduce the need for intubation and mechanical ventilation. Caffeine therapy often is needed for several weeks until the apnea resolves as the respiratory control of the infant matures. (See
         <a class="local">
          'Caffeine'
         </a>
         below.)
        </p>
        <p>
         In addition, early nasal continuous positive airway pressure (nCPAP) is often initiated in preterm infants &lt;32 weeks gestation and almost all EPT infants who are at risk for neonatal respiratory distress. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4997.html" rel="external">
          "Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Nasal continuous positive airway pressure (nCPAP)'
         </a>
         .)
        </p>
        <p>
         Other preventive measures that are applied to all neonates &lt;35 weeks gestation include maintaining a stable thermal environment, ensuring proper head and neck position, and maintaining nasal patency. (See
         <a class="local">
          'General measures'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H582727673">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of apnea of prematurity is instituted if:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Apneic spells are frequent, prolonged, or associated with bradycardia or frequent oxygen desaturation. In our practice, we use an oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) threshold of ≤85 percent. (See
         <a class="local">
          'Clinically significant apnea'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          OR
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The infant requires intervention with bag and mask ventilation, or multiple episodes of tactile stimulation.
        </p>
        <p>
        </p>
        <p>
         Management is a combination of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         General measures that reduce the risk of apnea or its associated hypoxemia (see
         <a class="local">
          'General measures'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasal continuous positive airway pressure (nCPAP) (see
         <a class="local">
          'Nasal continuous positive airway pressure'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          Caffeine
         </a>
         therapy (see
         <a class="local">
          'Caffeine'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         Patients who fail to respond to these interventions require intubation and mechanical ventilation or may be candidates for nasal intermittent positive pressure ventilation (NIPPV). (See
         <a class="local">
          'Nasal intermittent positive pressure ventilation'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5032.html" rel="external">
          "Overview of mechanical ventilation in neonates"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          GENERAL MEASURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         General measures are usually preventive in nature and are applied to all infants less than 35 weeks gestation who are at risk for apnea. These interventions are directed towards eliminating factors that increase the risk of apnea or reduce the prevalence of associated hypoxia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Environmental temperature control – A servo-controlled radiant warmer or incubator is used to provide a stable thermal environment, thereby eliminating temperature fluctuations that precipitate apneic episodes. (See
         <a class="medical medical_review" href="/z/d/html/5052.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consider underlying causes of new onset of apnea or increased severity, such as neonatal sepsis. Temperature instability may be a manifestation of sepsis. (See
         <a class="medical medical_review" href="/z/d/html/5052.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Head and neck position – Infants are positioned to avoid extreme flexion or extension of the neck, which decreases the patency of the upper airway. (See
         <a class="medical medical_review" href="/z/d/html/5052.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity", section on 'Upper airway patency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintain nasal patency – Nasal patency is preserved by avoiding vigorous nasal suctioning. (See
         <a class="medical medical_review" href="/z/d/html/5052.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity", section on 'Upper airway patency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oxygen supplementation to maintain oxygen saturation (SpO
         <sub>
          2
         </sub>
         ) at 90 to 95 percent – We provide oxygen supplementation to avoid baseline hypoxemia, which predisposes to episodes of severe oxygen desaturation. We use pulse oximetry to monitor SpO
         <sub>
          2
         </sub>
         in infants with apnea. (See
         <a class="medical medical_review" href="/z/d/html/112392.html" rel="external">
          "Neonatal target oxygen levels for preterm infants", section on 'Oxygen target levels'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2805809733">
         <span class="h1">
          RESPIRATORY SUPPORT
         </span>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Nasal continuous positive airway pressure
         </span>
         <span class="headingEndMark">
          —
         </span>
         For preterm infants with clinically significant apnea (ie, respiratory pauses &gt;20 seconds or a shorter duration accompanied by oxygen desaturation and/or bradycardia), we suggest nasal continuous positive airway pressure (nCPAP) [
         <a href="#rid2">
          2
         </a>
         ]. Many preterm infants may have other indications for nCPAP. For example, nCPAP is often initiated in preterm infants &lt;32 weeks gestation and almost all extremely preterm (gestational age &lt;28 weeks) who are at risk for neonatal respiratory distress. (See
         <a class="medical medical_review" href="/z/d/html/4997.html" rel="external">
          "Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Nasal continuous positive airway pressure (nCPAP)'
         </a>
         .)
        </p>
        <p>
         nCPAP is typically applied using nasal prongs. In the smallest infants, a nasal mask or nasal cannula may be used to minimize nasal trauma. In our practice, nCPAP is initiated at 4 to 6 cm H
         <sub>
          2
         </sub>
         O pressure. Although data are lacking, some clinicians may increase nCPAP pressure in an attempt to optimize FRC based on estimating lung volume on chest radiography. However, many of these infants have good lung compliance, and pressures above 8 cm H
         <sub>
          2
         </sub>
         O may overdistend the lungs or impair circulatory function.
        </p>
        <p>
         Nasal suctioning and/or frequent changing of the nCPAP prongs should be minimized to avoid irritation, unless nasal secretions are obstructing airflow.
        </p>
        <p>
         nCPAP reduces the incidence of mixed and obstructive apnea, maintains functional residual capacity (FRC), and alters timing of breathing in preterm infants [
         <a href="#rid3">
          3,4
         </a>
         ]. nCPAP is thought to be effective by splinting the pharyngeal airway with positive pressure, thereby reducing the risk of upper airway collapse and obstruction. nCPAP decreases respiratory frequency, primarily by prolongation of expiratory time, without altering ventilatory response to CO
         <sub>
          2
         </sub>
         [
         <a href="#rid5">
          5
         </a>
         ]. CPAP also increases oxygenation by improving ventilation-perfusion matching and provides continuous distending pressure that optimizes FRC [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5052.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity", section on 'Upper airway patency'
         </a>
         .)
        </p>
        <p>
         The efficacy of nCPAP for treating respiratory insufficiency in preterm neonates is described in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4997.html" rel="external">
          "Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Nasal continuous positive airway pressure (nCPAP)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2290702971">
         <span class="h2">
          High flow nasal cannula
         </span>
         <span class="headingEndMark">
          —
         </span>
         Humidified high flow nasal cannula (HFNC) has also been used to treat apnea of prematurity [
         <a href="#rid6">
          6
         </a>
         ]. HFNC is an effective method to provide oxygen supplementation and deliver CPAP while minimizing patient discomfort, but the amount of positive end-expiratory pressure (PEEP) generated by HFNC is highly unpredictable. This modality and its limitations are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'High-flow nasal cannula'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H557063937">
         <span class="h2">
          Low flow nasal cannula
         </span>
         <span class="headingEndMark">
          —
         </span>
         Low flow nasal cannula can be used with a blender to administer a low oxygen concentration at a flow rate of 1 to 2 L/min. This may provide a small amount of PEEP (approximately 1 to 3 cm H
         <sub>
          2
         </sub>
         O) without exposing the neonate to high oxygen concentrations. However, like HFNC, the amount of PEEP generated is unpredictable. (See
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'Low-flow nasal cannula'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H450997925">
         <span class="h2">
          Nasal intermittent positive pressure ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nasal intermittent positive pressure ventilation (NIPPV) is an augmentation of CPAP, which superimposes inflations set to a peak pressure delivered through nasal prongs or mask. NIPPV may be a useful tool to augment the beneficial effects of CPAP in preterm infants with apnea [
         <a href="#rid7">
          7,8
         </a>
         ]. It is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'Nasal intermittent positive pressure ventilation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2892455458">
         <span class="h2">
          Mechanical ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants who continue to have clinically significant apnea despite noninvasive respiratory support (CPAP or NIPPV) and
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         therapy generally require intubation and mechanical ventilation, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/130240.html" rel="external">
          "Approach to mechanical ventilation in very preterm neonates", section on 'Indications for invasive MV'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          CAFFEINE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methylxanthines are the primary pharmacologic therapy used to treat apnea of prematurity. The two methylxanthines used in apnea of prematurity are
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">
          theophylline
         </a>
         . Caffeine is the preferred agent because of its longer half-life, wider margin of safety, and lower frequency of adverse effects [
         <a href="#rid1">
          1,9
         </a>
         ]. (See
         <a class="local">
          'Caffeine versus theophylline'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3294539856">
         <span class="h2">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          Caffeine
         </a>
         is appropriate in the following settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment of infants who have documented apneic spells that are frequent, prolonged, or associated with bradycardia and/or oxygen desaturation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment in infants who have apneic spells that require intervention with bag and mask ventilation, or multiple episodes of tactile stimulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As prophylactic therapy given to extremely preterm infants (EPT; gestational age &lt;28 weeks) to reduce the need for intubation and mechanical ventilation, and to decrease associated morbidities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To facilitate extubation in EPT neonates who are intubated.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3625170136">
         <span class="h2">
          Dosing and monitoring
         </span>
        </p>
        <p class="headingAnchor" id="H2700886554">
         <span class="h3">
          Initial and maintenance dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dosing for
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         , regardless of indication (treatment versus prophylaxis), is as follows [
         <a href="#rid10">
          10,11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A loading dose of 20 mg/kg of
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         citrate (equivalent to 10 mg/kg caffeine base) is given intravenously (IV) or enterally.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A daily maintenance dose of 5 to 10 mg/kg per dose (equivalent to 2.5 to 5 mg/kg
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         base) is started 24 hours after the loading dose, which can also be administered either IV or orally.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After the first weeks of therapy, increased dosing may be needed due to faster metabolism with advancing maturation [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The efficacy and safety of higher doses are uncertain. Limited clinical trial data suggest that high-dose
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         may reduce the risk of bronchopulmonary dysplasia (BPD) compared with standard dosing [
         <a href="#rid13">
          13,14
         </a>
         ]. However, the safety of high-dose caffeine has not been established.
        </p>
        <p class="headingAnchor" id="H2569838476">
         <span class="h3">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine measurement of serum drug concentration is
         <strong>
          not
         </strong>
         necessary. This is because
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         has a wide therapeutic index and serious adverse effects are uncommon [
         <a href="#rid15">
          15
         </a>
         ]. In addition, the dose-response relationship is not established. Drug levels are usually only necessary in the rare patient who develops signs of toxicity.
        </p>
        <p class="headingAnchor" id="H1969851401">
         <span class="h3">
          Discontinuation of caffeine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data are lacking on when to discontinue
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         therapy. Our approach, which is based on our experience and the natural course of apnea of prematurity, is as follows (see
         <a class="medical medical_review" href="/z/d/html/5052.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity", section on 'Natural history'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We discontinue
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         when the infant reaches a postmenstrual age (PMA) between 32 and 34 weeks and there have been no apneic episodes requiring intervention for approximately five days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We then continue cardiorespiratory monitoring until discharge or for at least ten days after stopping
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         , whichever is longer. The mean half-life of caffeine in preterm neonates is approximately 85 hours [
         <a href="#rid16">
          16
         </a>
         ]. Thus, it takes up to seven days for caffeine to be eliminated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          Caffeine
         </a>
         rarely needs to be reinstituted, but if there are frequent episodes of apnea, bradycardia, or oxygen desaturation, or if the infant requires intervention with a bag and mask, caffeine therapy may be restarted. (See
         <a class="local">
          'Management overview'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Limited data that suggest prolonged
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         therapy beyond 35 weeks PMA may decrease the frequency and severity of intermittent hypoxemia [
         <a href="#rid17">
          17,18
         </a>
         ]. Clinical studies are being conducted to further investigate the role of caffeine therapy in reducing intermittent hypoxemia.
        </p>
        <p class="headingAnchor" id="H2714216856">
         <span class="h3">
          Response failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants who continue to have clinically significant apnea despite
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         therapy and continuous positive airway pressure (CPAP) require intubation and mechanical ventilation or may be candidates for nasal intermittent positive pressure ventilation (NIPPV). (See
         <a class="medical medical_review" href="/z/d/html/5032.html" rel="external">
          "Overview of mechanical ventilation in neonates"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'Nasal intermittent positive pressure ventilation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Efficacy of methylxanthines
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of methylxanthines for treating apnea of prematurity is supported by clinical trials and meta-analyses [
         <a href="#rid10">
          10,19-22
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapeutic use of
         </strong>
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         – The major clinical trial that established the efficacy and safety of caffeine in this setting was the Caffeine for Apnea of Prematurity (CAP) trial [
         <a href="#rid10">
          10
         </a>
         ]. It enrolled &gt;2000 preterm infants (birth weight [BW] between 500 and 1250 g) and randomly assigned them to caffeine or placebo. In 41 percent of enrolled patients, the indication for caffeine therapy was to treat documented apnea, in 36 percent it was to facilitate extubation, and in the remaining 23 percent it was given to prevent apnea. In this trial, caffeine reduced the incidence of BPD (36 versus 47 percent; adjusted odds ratio [aOR] 0.63, 95% CI 0.52-0.76) and reduced the need for patent ductus arteriosus (PDA) ligation (4 versus 13 percent; RR 0.32, 95% CI 0.22-0.45). The reduction is BPD was attributed to reduced need for positive pressure ventilation (PPV) among caffeine-treated infants. Mortality was similar in both groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a post-hoc subgroup analysis of the CAP trial, the benefit of
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         in reducing BPD was greater among infants who were intubated or on noninvasive ventilation at the time of randomization compared with those who were not receiving PPV [
         <a href="#rid20">
          20
         </a>
         ]. In addition, greater benefit was observed in infants started on caffeine on or before three days than between 4 and 10 days of age [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A follow-up study of the CAP trial reported outcomes of survivors at 18 to 21 months corrected age [
         <a href="#rid11">
          11
         </a>
         ]. Infants in the
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         group had a lower incidence of cerebral palsy (CP) (4 versus 7 percent; aOR 0.58, 95% CI 0.39-0.87) and cognitive delay (34 versus 38 percent; aOR 0.81, 95% CI 0.66-0.99). At five-year follow-up, the difference between groups for these outcomes was no longer statistically significant (for CP: 1.6 versus 2.7 percent; aOR 0.59, 95 % CI 0.29-1.18; for cognitive delay: 4.9 versus 5.1 percent; aOR 0.97; 95% CI, 0.61-1.55) [
         <a href="#rid23">
          23
         </a>
         ]. However, the study detected a difference in the incidence of any motor impairment at five years, including very mild impairment (9 versus 14 percent; aOR 0.66, 95% CI 0.48-0.91). Follow-up of the CAP cohort at 11 years of age reported that children in the caffeine group had better respiratory function compared with controls [
         <a href="#rid24">
          24
         </a>
         ]. Additional data on long-term neurodevelopmental outcomes are discussed below. (See
         <a class="local">
          'Long-term neurodevelopmental outcome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The results of the CAP trial support the use of
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         in intubated preterm neonates as a means of facilitating extubation since this subgroup comprised over one-third of the trial population. In a post-hoc subgroup analysis of the CAP trial, the benefit of caffeine was similar in this subgroup of patients as it was for the overall trial population [
         <a href="#rid20">
          20
         </a>
         ]. A subsequent small trial in which intubated preterm neonates were randomized to early caffeine treatment or placebo, the duration of mechanical ventilation was similar in both groups [
         <a href="#rid25">
          25
         </a>
         ]. The trial was stopped early after enrolling only 82 patients due to a cautious decision of the data safety and monitoring board. As such, it is likely that the trial was underpowered to detect a difference between the two treatment arms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prophylactic use
         </strong>
         – Prophylactic use of
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         in EPT infants is supported by the CAP trial (discussed above), in which the indication for caffeine therapy for approximately one-quarter of the trial population was to prevent apnea [
         <a href="#rid10">
          10
         </a>
         ]. In a post-hoc subgroup analysis of the CAP trial, the benefit of caffeine was consistent regardless of the indication [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional supporting evidence comes from observational studies [
         <a href="#rid21">
          21,26
         </a>
         ]. In a large retrospective study from the Canadian Neonatal Network (CNN), 75 percent of EPT infants received
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         within the first day after birth and the remaining patients received caffeine at a later time [
         <a href="#rid21">
          21
         </a>
         ]. In a multivariate analysis, early caffeine was associated with lower risk of BPD (aOR 0.79, 95% CI 0.64-0.96) and lower likelihood of needing surgical ligation for PDA (aOR 0.58, 95% CI 0.42-0.8). A follow-up report of this observational cohort at 18 to 24 months corrected age reported that early caffeine use was associated with better neurodevelopment [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similar findings were reported in a large cohort study using data from the Pediatrix Medical Group, in which early
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         therapy before three days of life was associated with a lower incidence of BPD compared with later use (on or after three days of life) (23 versus 31 percent; OR 0.68, 95% CI, 0.63-0.73), shorter duration of mechanical ventilation (mean difference six days), and less need for treatment of PDA (OR 0.60; 95% CI, 0.55-0.65) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, another observational study did not detect a difference in the need for respiratory support between infants who received early
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         therapy compared with later treatment [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3571512726">
         <span class="h2">
          Caffeine versus theophylline
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         as the preferred methylxanthine for the treatment of apnea of prematurity. Caffeine has the following therapeutic advantages over
         <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">
          theophylline
         </a>
         [
         <a href="#rid15">
          15,28,29
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Longer half-life (65 to 100 hours), which means that
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         can be administered once daily instead of the more frequent dosing required for
         <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">
          theophylline
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More reliable enteral absorption.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wide therapeutic index, which minimizes side effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Less need for therapeutic monitoring –
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          Caffeine
         </a>
         levels are usually only measured if there are signs of toxicity, whereas
         <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">
          theophylline
         </a>
         therapy generally requires frequent monitoring of serum levels because of the smaller safety margin and greater variability in absorption [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         In a meta-analysis of five small trials (108 infants) comparing
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         with
         <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">
          theophylline
         </a>
         , both agents had similar efficacy for reducing episodes of apnea and bradycardia during the first week [
         <a href="#rid29">
          29
         </a>
         ]. However, adverse reactions (ie, tachycardia and feeding intolerance) were considerably lower with caffeine (3 versus 31 percent; RR 0.17, 95% CI 0.04-0.72).
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main adverse effects of methylxanthine treatment is tachycardia, which occurs less frequently with
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         than with
         <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">
          theophylline
         </a>
         [
         <a href="#rid30">
          30
         </a>
         ]. Theophylline can cause gastroesophageal reflux, perhaps because of delayed gastric emptying [
         <a href="#rid31">
          31
         </a>
         ]; however, this does not present as a clinically significant problem.
        </p>
        <p>
         Methylxanthines also increase metabolic rate [
         <a href="#rid32">
          32
         </a>
         ]; however, the long-term impact of these effects is not known. In a study of metabolic rate and oxygen consumption,
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         significantly increased oxygen consumption (7 to 8.8 mL/kg per min) and energy expenditure (2.1 to 3 kcal/kg per hour) compared with baseline measurements [
         <a href="#rid33">
          33
         </a>
         ]. During the four-week study period, treated infants required a lower incubator temperature to maintain normal body temperature and had less weight gain with similar caloric intake than untreated infants (21 versus 42 g/day).
        </p>
        <p class="headingAnchor" id="H3810800768">
         <span class="h2">
          Long-term neurodevelopmental outcome
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, based upon follow-up data from the CAP trial,
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         appears to improve neurodevelopmental outcomes at 18 to 24 months corrected age, though it is uncertain whether the benefit is sustained in later childhood. (See
         <a class="local">
          'Efficacy of methylxanthines'
         </a>
         above.)
        </p>
        <p>
         Other follow-up studies of the CAP trial reported similar overall cognitive outcome and academic performances between the two groups at 5 and 11 years of age [
         <a href="#rid23">
          23,34,35
         </a>
         ] but neonatal
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         therapy reduced rates of developmental coordination disorder at five years of age and motor impairment at 11 years of age [
         <a href="#rid34">
          34,36
         </a>
         ]. In addition, the caffeine-treated group at 11 years of age performed better than the control group on tests for fine motor coordination, visuomotor integration, visual perception, and visuospatial organization [
         <a href="#rid35">
          35
         </a>
         ]. These data support the long-term safety and potential efficacy of caffeine therapy for apnea of prematurity.
        </p>
        <p class="headingAnchor" id="H4291301468">
         <span class="h2">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methylxanthines are competitive inhibitors of adenosine receptors. Because adenosine is an inhibitory neuromodulator of respiratory drive, blockage of its receptors by methylxanthines results in increased ventilatory responsiveness to carbon dioxide, reversal of central hypoxic depression of breathing, enhanced force of diaphragmatic contraction, and improved pharyngeal muscle tone [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Physiologic changes that occur shortly after administering intravenous
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         in preterm neonates include increases in cerebral cortical activity, respiratory neural output, and diaphragmatic contraction; decreased carbon dioxide partial pressure; and increased arterial blood pressure [
         <a href="#rid32">
          32,38
         </a>
         ]. Caffeine may also reduce the effects of hypoxia on perinatal white matter injury [
         <a href="#rid37">
          37
         </a>
         ]. Some of the effects of caffeine may be due to its ability to inhibit pro- and anti-inflammatory mechanisms, which are mediated by the various adenosine receptor subtypes [
         <a href="#rid39">
          39-41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          ROLE OF TRANSFUSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Red blood cell (RBC) transfusion may be warranted in neonates with anemia (hematocrit &lt;25 to 30 percent) who have frequent and/or severe apnea despite
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         therapy. Indications for transfusion in the preterm infants are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5041.html" rel="external">
          "Red blood cell (RBC) transfusions in the neonate", section on 'Indications for transfusion'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4962.html" rel="external">
          "Anemia of prematurity (AOP)", section on 'Transfusion'
         </a>
         .)
        </p>
        <p>
         The frequency and severity of apnea occasionally are increased in preterm infants who develop significant anemia at one to two months of age. Observational studies have demonstrated improvements in apneic and/or desaturation episodes temporally associated with RBC transfusion [
         <a href="#rid42">
          42-44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H874090019">
         <span class="h1">
          DISCHARGE PLANNING
         </span>
         <span class="headingEndMark">
          —
         </span>
         At discharge, home cardiorespiratory monitoring is
         <strong>
          not
         </strong>
         needed for infants who are otherwise ready for discharge and remain free of any episode of apnea, bradycardia, or oxygen desaturation for five to seven days, as the risk of a subsequent clinically significant apnea event is very low [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         However if a preterm infant is ready for discharge, but mild apnea continues to be a concern, it remains uncertain what is the optimal approach [
         <a href="#rid1">
          1
         </a>
         ]. Many of these infants have persistent mild bradycardia and/or desaturation events that are detected by cardiorespiratory monitoring, which are associated with short undetected respiratory pauses as they remain below the apnea alarm threshold. These events are probably of no clinical significance. If
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         has only recently been discontinued, we generally advise that the infant not be discharged home unless there is an event-free period of 10 days to allow caffeine to be either eliminated or reach low subtherapeutic levels. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
         Discharge criteria vary. Most centers wait until infants are free of apnea and off
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         therapy before discharge, while some may discharge infants home with cardiorespiratory monitoring, and on or off caffeine therapy. If the infant is to be monitored at home, the parents/caregivers or primary home care provider must receive training in cardiorespiratory resuscitation prior to discharge and must demonstrate proficiency in managing the monitor and providing stimulation. Such home monitoring can almost always be discontinued at around 43 to 44 weeks postmenstrual age (PMA). Implementation of home cardiorespiratory monitoring in infants, including discontinuation, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6349.html" rel="external">
          "Use of home cardiorespiratory monitors in infants", section on 'Preterm infants with persistent symptoms related to apnea of prematurity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1478258458">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/129741.html" rel="external">
          "Society guideline links: Apnea of prematurity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H116325052">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – Initial cardiorespiratory monitoring is provided for all preterm infants admitted to a neonatal intensive care unit (NICU), as they are at risk for apnea. (See
         <a class="local">
          'Monitoring'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5052.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of apnea of prematurity", section on 'Incidence'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – Supportive care is focused on eliminating factors that increase the risk of apnea. It includes maintenance of a stable thermal environment and nasal patency, avoidance of extreme neck flexion and extension, and identifying any other underlying condition associated with apnea (eg, sepsis). (See
         <a class="local">
          'General measures'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/112392.html" rel="external">
          "Neonatal target oxygen levels for preterm infants", section on 'Oxygen target levels'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management approach
         </strong>
         – Our approach to managing preterm infants with documented apnea and those at high risk of apnea (eg, extremely low birth weight [ELBW] infants [BW &lt;1000 g] and/or extremely preterm [EPT] infants [gestational age &lt;28 weeks]) is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          nCPAP
         </strong>
         – For preterm infants with clinically significant apnea (ie, respiratory pauses &gt;20 seconds or a shorter duration accompanied by oxygen desaturation and/or bradycardia), we suggest nasal continuous positive airway pressure (nCPAP) rather than other respiratory modalities or supportive care alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Many preterm infants may have other indications for nCPAP (eg, nCPAP is commonly used for management of respiratory distress syndrome and it is used routinely in most EPT infants). nCPAP is typically started at a pressure between 4 and 6 cm H
         <sub>
          2
         </sub>
         O via nasal prongs or mask. (See
         <a class="local">
          'Nasal continuous positive airway pressure'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4997.html" rel="external">
          "Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Nasal continuous positive airway pressure (nCPAP)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indications for
         </strong>
         <strong>
          caffeine
         </strong>
         – For infants with apnea of prematurity who require repeated tactile stimulation or ventilatory support, we recommend
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         rather than
         <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">
          theophylline
         </a>
         or supportive care alone (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Caffeine and theophylline appear to have similar efficacy for reducing episodes of apnea and bradycardia in preterm infants; however, the risk of adverse effects is substantially lower with caffeine. In addition, caffeine has the advantage of more reliable enteral absorption, and it does not require routine therapeutic monitoring. (See
         <a class="local">
          'Caffeine versus theophylline'
         </a>
         above and
         <a class="local">
          'Efficacy of methylxanthines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In addition, we suggest early prophylactic
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         therapy for ELBW or EPT infants (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Caffeine is typically started within the first two days after birth. Apnea occurs in nearly all of these infants and the available evidence suggests that prophylactic caffeine reduces the need for intubation and mechanical ventilation and may facilitate earlier extubation. (See
         <a class="local">
          'Indications'
         </a>
         above and
         <a class="local">
          'Efficacy of methylxanthines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Caffeine
         </strong>
         <strong>
          dosing and maintenance
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          Caffeine
         </a>
         is given as a loading dose of 20 mg/kg of caffeine citrate (equivalent to 10 mg/kg caffeine base), followed in 24 hours by a daily maintenance dose of 5 to 10 mg/kg per dose (equivalent to 2.5 to 5 mg/kg caffeine base). Both the loading and maintenance doses can be administered intravenously or orally. Routine measurement of serum drug concentration is
         <strong>
          not
         </strong>
         necessary unless there are signs of toxicity. (See
         <a class="local">
          'Initial and maintenance dosing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Stopping
         </strong>
         <strong>
          caffeine
         </strong>
         – In our center, discontinuation of
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         can be discontinued when the infant is at a postmenstrual age postmenstrual age (PMA) between 32 and 34 weeks and has had a five-day period free of any apnea, bradycardia, or desaturation alarm events. (See
         <a class="local">
          'Discontinuation of caffeine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transfusion
         </strong>
         – Red blood cell (RBC) transfusion is often warranted for infants who are anemic (eg, hematocrit &lt;25 percent) and have frequent and/or severe apnea requiring intervention despite
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         therapy. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5041.html" rel="external">
          "Red blood cell (RBC) transfusions in the neonate", section on 'Indications for transfusion'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4962.html" rel="external">
          "Anemia of prematurity (AOP)", section on 'Transfusion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Discharge planning
         </strong>
         – At discharge, home cardiorespiratory monitoring is
         <strong>
          not
         </strong>
         necessary for infants who are otherwise ready for discharge and remain free of any episode of apnea, bradycardia, or oxygen desaturation for five to seven days. (See
         <a class="local">
          'Discharge planning'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If an infant is ready for discharge, but mild apnea (ie, apneic episodes &gt;15 seconds that do not require intervention and are not accompanied with bradycardia and desaturation) continues to be a concern, home cardiorespiratory monitoring may be considered until the infant is 43 to 44 weeks PMA. Prior to discharge, the parents/caregivers or primary home care provider must receive training in cardiorespiratory resuscitation and must demonstrate proficiency in managing the monitor and providing stimulation. (See
         <a class="medical medical_review" href="/z/d/html/6349.html" rel="external">
          "Use of home cardiorespiratory monitors in infants", section on 'Implementation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Infants still exhibiting apnea with associated bradycardia or oxygen desaturation are
         <strong>
          not
         </strong>
         candidates for discharge and home monitoring.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Eichenwald EC, Committee on Fetus and Newborn, American Academy of Pediatrics. Apnea of Prematurity. Pediatrics 2016; 137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kattwinkel J, Nearman HS, Fanaroff AA, et al. Apnea of prematurity. Comparative therapeutic effects of cutaneous stimulation and nasal continuous positive airway pressure. J Pediatr 1975; 86:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller MJ, Carlo WA, Martin RJ. Continuous positive airway pressure selectively reduces obstructive apnea in preterm infants. J Pediatr 1985; 106:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stark AR, Goldman MD, Frantz ID 3rd. Lung volume changes, occlusion pressure and chest wall configuration in human infants. Pediatr Res 1979; 13:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durand M, McCann E, Brady JP. Effect of continuous positive airway pressure on the ventilatory response to CO2 in preterm infants. Pediatrics 1983; 71:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sreenan C, Lemke RP, Hudson-Mason A, Osiovich H. High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure. Pediatrics 2001; 107:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemyre B, Davis PG, de Paoli AG. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for apnea of prematurity. Cochrane Database Syst Rev 2002; :CD002272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Firestone K, Horany BA, de Leon-Belden L, Stein H. Nasal continuous positive airway pressure versus noninvasive NAVA in preterm neonates with apnea of prematurity: a pilot study with a novel approach. J Perinatol 2020; 40:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puia-Dumitrescu M, Smith PB, Zhao J, et al. Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants. J Pediatr 2019; 211:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354:2112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007; 357:1893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch G, Datta AN, Jost K, et al. Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates. J Pediatr 2017; 191:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vliegenthart R, Miedema M, Hutten GJ, et al. High versus standard dose caffeine for apnoea: a systematic review. Arch Dis Child Fetal Neonatal Ed 2018; 103:F523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brattström P, Russo C, Ley D, Bruschettini M. High-versus low-dose caffeine in preterm infants: a systematic review and meta-analysis. Acta Paediatr 2019; 108:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Natarajan G, Botica ML, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? Pediatrics 2007; 119:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doyle J, Davidson D, Katz S, et al. Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge. J Perinatol 2016; 36:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhein LM, Dobson NR, Darnall RA, et al. Effects of caffeine on intermittent hypoxia in infants born prematurely: a randomized clinical trial. JAMA Pediatr 2014; 168:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobson NR, Rhein LM, Darnall RA, et al. Caffeine decreases intermittent hypoxia in preterm infants nearing term-equivalent age. J Perinatol 2017; 37:1135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson-Smart DJ, De Paoli AG. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev 2010; :CD000140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis PG, Schmidt B, Roberts RS, et al. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. J Pediatr 2010; 156:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodha A, Seshia M, McMillan DD, et al. Association of early caffeine administration and neonatal outcomes in very preterm neonates. JAMA Pediatr 2015; 169:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodha A, Entz R, Synnes A, et al. Early Caffeine Administration and Neurodevelopmental Outcomes in Preterm Infants. Pediatrics 2019; 143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt B, Anderson PJ, Doyle LW, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012; 307:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doyle LW, Ranganathan S, Cheong JLY. Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth. Am J Respir Crit Care Med 2017; 196:1318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amaro CM, Bello JA, Jain D, et al. Early Caffeine and Weaning from Mechanical Ventilation in Preterm Infants: A Randomized, Placebo-Controlled Trial. J Pediatr 2018; 196:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobson NR, Patel RM, Smith PB, et al. Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants. J Pediatr 2014; 164:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel RM, Zimmerman K, Carlton DP, et al. Early Caffeine Prophylaxis and Risk of Failure of Initial Continuous Positive Airway Pressure in Very Low Birth Weight Infants. J Pediatr 2017; 190:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aranda JV, Cook CE, Gorman W, et al. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr 1979; 94:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson-Smart DJ, Steer PA. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev 2010; :CD000273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steer PA, Henderson-Smart DJ. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev 2000; :CD000273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gounaris A, Kokori P, Varchalama L, et al. Theophylline and gastric emptying in very low birthweight neonates: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2004; 89:F297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Supcun S, Kutz P, Pielemeier W, Roll C. Caffeine increases cerebral cortical activity in preterm infants. J Pediatr 2010; 156:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer J, Maier K, Linderkamp O, Hentschel R. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics 2001; 107:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt B, Roberts RS, Anderson PJ, et al. Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. JAMA Pediatr 2017; 171:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mürner-Lavanchy IM, Doyle LW, Schmidt B, et al. Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. Pediatrics 2018; 141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doyle LW, Schmidt B, Anderson PJ, et al. Reduction in developmental coordination disorder with neonatal caffeine therapy. J Pediatr 2014; 165:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Shaweesh JM, Martin RJ. Neonatal apnea: what's new? Pediatr Pulmonol 2008; 43:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraaijenga JV, Hutten GJ, de Jongh FH, van Kaam AH. The Effect of Caffeine on Diaphragmatic Activity and Tidal Volume in Preterm Infants. J Pediatr 2015; 167:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin RJ, Wang K, Köroğlu O, et al. Intermittent hypoxic episodes in preterm infants: do they matter? Neonatology 2011; 100:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köroğlu OA, MacFarlane PM, Balan KV, et al. Anti-inflammatory effect of caffeine is associated with improved lung function after lipopolysaccharide-induced amnionitis. Neonatology 2014; 106:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weichelt U, Cay R, Schmitz T, et al. Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine. Eur Respir J 2013; 41:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zagol K, Lake DE, Vergales B, et al. Anemia, apnea of prematurity, and blood transfusions. J Pediatr 2012; 161:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu Jawdeh EG, Martin RJ, Dick TE, et al. The effect of red blood cell transfusion on intermittent hypoxemia in ELBW infants. J Perinatol 2014; 34:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovatis KZ, Di Fiore JM, Martin RJ, et al. Effect of Blood Transfusions on Intermittent Hypoxic Episodes in a Prospective Study of Very Low Birth Weight Infants. J Pediatr 2020; 222:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorch SA, Srinivasan L, Escobar GJ. Epidemiology of apnea and bradycardia resolution in premature infants. Pediatrics 2011; 128:e366.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5048 Version 45.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26628729" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Apnea of Prematurity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1092821" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Apnea of prematurity. Comparative therapeutic effects of cutaneous stimulation and nasal continuous positive airway pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3917503" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Continuous positive airway pressure selectively reduces obstructive apnea in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/471585" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Lung volume changes, occlusion pressure and chest wall configuration in human infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6403913" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Effect of continuous positive airway pressure on the ventilatory response to CO2 in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11331690" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11869635" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for apnea of prematurity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32218494" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Nasal continuous positive airway pressure versus noninvasive NAVA in preterm neonates with apnea of prematurity: a pilot study with a novel approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31101409" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16707748" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Caffeine therapy for apnea of prematurity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17989382" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Long-term effects of caffeine therapy for apnea of prematurity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29173321" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29437799" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : High versus standard dose caffeine for apnoea: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30242903" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : High-versus low-dose caffeine in preterm infants: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17473094" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26562367" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24445955" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Effects of caffeine on intermittent hypoxia in infants born prematurely: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28749480" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Caffeine decreases intermittent hypoxia in preterm infants nearing term-equivalent age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21154343" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Methylxanthine treatment for apnoea in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19926098" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25402629" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Association of early caffeine administration and neonatal outcomes in very preterm neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30518670" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Early Caffeine Administration and Neurodevelopmental Outcomes in Preterm Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22253394" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28707987" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29519541" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Early Caffeine and Weaning from Mechanical Ventilation in Preterm Infants: A Randomized, Placebo-Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24461786" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28890204" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Early Caffeine Prophylaxis and Risk of Failure of Initial Continuous Positive Airway Pressure in Very Low Birth Weight Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/430317" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pharmacokinetic profile of caffeine in the premature newborn infant with apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20091506" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Caffeine versus theophylline for apnea in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796190" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Caffeine versus theophylline for apnea in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15210659" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Theophylline and gastric emptying in very low birthweight neonates: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20176190" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Caffeine increases cerebral cortical activity in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11335740" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28437520" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29643070" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24840756" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Reduction in developmental coordination disorder with neonatal caffeine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18780339" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Neonatal apnea: what's new?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25982138" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The Effect of Caffeine on Diaphragmatic Activity and Tidal Volume in Preterm Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21986336" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Intermittent hypoxic episodes in preterm infants: do they matter?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25011471" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Anti-inflammatory effect of caffeine is associated with improved lung function after lipopolysaccharide-induced amnionitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22878872" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22494873" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Anemia, apnea of prematurity, and blood transfusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24921411" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The effect of red blood cell transfusion on intermittent hypoxemia in ELBW infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32423683" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Effect of Blood Transfusions on Intermittent Hypoxic Episodes in a Prospective Study of Very Low Birth Weight Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21746726" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Epidemiology of apnea and bradycardia resolution in premature infants.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
